Vir Biotechnology
VIR
8.39
-0.48
-5.41%
Vir Biotechnology
US · VIR
#2824 by market cap
Listed 2019
8.39
-0.48
-5.41%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Vir Biotechnology
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
- Founded
- 2016
- CEO
- Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD
- Employees
- 367
- Headquarters
- San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- vir.bio
Company profile
- Exchange
- US
- Symbol
- VIR
- Market-cap rank
- #2824
- Listing date
- 2019-10-11
- Market cap
- 1.56B
- Float cap
- 1.31B
- Shares out
- 186.27M
- Float shares
- 156.08M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vir Biotechnology discussion 0 comments